Rentschler enters agreement with Genmab for antibody manufacture
Rentschler will manufacture Genmab’s bispecific antibodies and expand the US site where the work will take place.
Rentschler will manufacture Genmab’s bispecific antibodies and expand the US site where the work will take place.
Reports suggest US government has selected five companies with the most promising vaccine leads to be given additional financial and infrastructure support.